SANOFI-AVENTIS (EPA:SAN) Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
Transparency directive : regulatory news
17/04/2024 07:00
SANOFI-AVENTIS's latest news
17/04/2024 07:00
12/04/2024 20:05
22/03/2024 07:30
15/03/2024 20:04
24/02/2024 15:51
23/02/2024 18:45
23/02/2024 07:00
22/02/2024 19:02
20/02/2024 23:40
15/02/2024 14:00
Other stories
30/04/2024 07:27
30/04/2024 03:02
30/04/2024 06:08
30/04/2024 05:01
30/04/2024 06:46
30/04/2024 07:29
29/04/2024 16:19
30/04/2024 07:06
29/04/2024 16:08
30/04/2024 00:15
29/04/2024 23:01
30/04/2024 03:01
29/04/2024 17:25
29/04/2024 18:13
30/04/2024 07:48
30/04/2024 04:03
29/04/2024 16:48
29/04/2024 19:23
29/04/2024 14:30
29/04/2024 12:07
30/04/2024 02:22
29/04/2024 21:26
29/04/2024 23:42
30/04/2024 03:00
29/04/2024 23:11
29/04/2024 21:00
29/04/2024 23:02
29/04/2024 20:23
30/04/2024 04:48
29/04/2024 23:50
29/04/2024 12:00
28/04/2024 19:21
29/04/2024 14:48
29/04/2024 22:10
30/04/2024 06:00
29/04/2024 21:01
28/04/2024 12:18
30/04/2024 01:08